I-mab share price logo

I-mab Share Price

NASDAQ: IMAB

Small Cap

$3.69

-0.03

(-0.67%)

as on

I-mab Stock Performance

as on September 18, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $3.52
    $3.8
    downward going graph

    4.61%

    Downside

    2.98%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $0.6
    $5.9
    downward going graph

    83.88%

    Downside

    59.89%

    Upside

    downward going graph

I-mab share price movements today

Previous Close
$3.72
Open
$3.63
Volume
1.9M
Day's Low - High
$3.52 - $3.8
52 Week Low - High
$0.6 - $5.9

I-mab Historical Returns

1 Month Return
-25.67 %
3 Month Return
+ 46.56 %
1 Year Return
+ 232.11 %
3 Year Return
-28.74 %
5 Year Return
0 %

I-mab Stock Fundamentals & Key Indicators

Check I-mab market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$303.8M

EPS (TTM)

-0.315

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-38.0M

Revenue (TTM)

3.5M

Profit Margin

0.00%

Return On Equity TTM

254300.00%

I-mab vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of I-mab with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$303.8MNANA0.00%
BUY$60.5B252.04%-505.15-12.96%
NA$39.0BNANA-3.89%
BUY$100.3B44.17%27.8531.86%
BUY$59.6B1.78%14.131.37%

Stock Returns calculator for I-mab Stock including INR - Dollar returns

The I-mab stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

I-mab investment value today

Current value as on today

₹3,43,130

Returns

₹2,43,130

(+243.13%)

Returns from I-mab Stock

₹2,38,532 (+238.53%)

Dollar Returns*

₹4,598 (+4.6%)

Analyst Recommendation on I-mab Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for I-mab. Average target price of $6.67

I-mab Share Price Target

Get share price movements and forecasts by analysts on I-mab.

What analysts predicted

44.68%UPSIDE

Target Price

$6.67

Current Price

$3.69

Analyzed by

11 Analysts

Target

$6.67

I-mab target price $6.67, a slight upside of 44.68% compared to current price of $3.69. According to 11 analysts rating.

I-mab Stock's Interest Amongst Investors

Investment in I-mab Shares on INDmoney has dropped by -9.16% over the past 30 days, indicating reduced transactional activity.

Time period: to

Change:-9.16% versus previous 30 day period

Search interest for I-mab Stock has increased by 177% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:177% versus previous 30 day period

I-mab Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
1
9
3
3
3
-
-
-
-
-
Gross Profit
1
9
3
-
3
-
-
-
-
-
Operating Income
-335
-335
-282
-139
-90
-15
-12
-12
-5
-7
EBITDA
-50
-12
-275
-
-84
-15
-12
-
-5
-7
Interest Expense
18
0
-
-
0
-
-
-
-
-
Depreciation
-
-
-
-
-
-
-
-
-
-
Income Before Tax
-386
-386
-346
-161
-69
-49
-20
-10
-3
-5
Income Tax Expense
0
8
-64
-
-90
-42
-
-
-
-
Net Income
-56
-386
-346
-66
20
25
-20
-9
-3
-5
Net Profit Margin
-3931.80%
-3931.80%
-8673.15%
-2045.32%
521.77%
0.00%
0.00%
0.00%
0.00%
0.00%

I-mab Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
1
7
4
235
13
-31
3
-
Gross Profit
1
7
4
235
6
-35
3
-
Operating Income
-280
-438
-1,464
155
-2,071
-1,969
-1,236
-375
EBITDA
-279
-431
-1,455
168
-2,057
-1,944
-1,212
-373
Interest Expense
0
1
0
0
2
0
0
-
Depreciation
1
6
15
23
34
63
52
0
Income Before Tax
-298
-401
-1,451
483
-2,334
-2,506
-1,465
-362
Income Tax Expense
-11
1
2
12
3
0
-1,258
-
Net Income
-45
-58
-211
71
-366
-359
-205
-162
Net Profit Margin
-2580.82%
-749.02%
-4950.00%
30.53%
-2648.70%
1131.65%
-5302.03%
0.00%

I-mab Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-386
-346
-346
20
180
-143
-9
-22
-5
Operating Cash Flow
-
-
-
-
-
-
-
-
-
Investing Cash Flow
-
-
-
-
-
-
-
-
-
Financing Cash Flow
-
-
-
-
-
-
-
-
-
Change in Cash
-225
-
-
-
-
-
-
-
-

I-mab Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Net Income
-402
-1,451
470
-2,331
-2,507
-206
-49
Operating Cash Flow
-280
-867
433
-973
-1,102
-1,304
-52
Investing Cash Flow
9
212
-201
-727
458
102
-136
Financing Cash Flow
1,479
152
3,440
593
42
7
0
Change in Cash
1,268
-487
3,565
-1,235
-212
-1,110
-1,706

Global Institutional Holdings in I-mab

Funds
Holdings
Hillhouse Capital Advisors, Ltd.
7.32%
SG Americas Securities, LLC
1.01%
Stonepine Capital Management Llc
0.59%
Two Sigma Advisers, LLC
0.44%
UBS Group AG
0.39%

Insights on I-mab

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, IMAB has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 3.27M → 3.99M (in $), with an average increase of 18.1% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 111.5% return, outperforming this stock by 138.9%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -3.15M → -5.50M (in $), with an average decrease of 74.7% per quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, IMAB stock has moved down by -27.5%

About I-mab

i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm
OrganisationI-mab
Headquarters2440 Research Boulevard, Rockville, MD, United States, 20850
IndustryHealth Technology
CEODr. Xi-Yong Fu M.B.A., Ph.D.
E-voting on sharesClick here to vote

Key Management of I-mab

Name

Title

Dr. Claire Xu M.D., Ph.D.

Senior Vice President of Clinical Development

Dr. Phillip Dennis M.D., Ph.D.

Chief Medical Officer

Mr. Sean Wuxiong Cao M.B.A., Ph.D.

Chief Business Development Officer & Independent Director

Mr. Wei Fu

Executive Chairman

Dr. Xi-Yong Fu M.B.A., Ph.D.

CEO & Director

Mr. Skelton Joseph

Chief Financial Officer

Mr. Tyler Ehler

Senior Director of Investor Relations

FAQs

What is I-mab share price today?

I-mab share price today is $3.69 as on at the close of the market. I-mab share today touched a day high of $3.8 and a low of $3.52.

What is the 52 week high and 52 week low for I-mab share?

I-mab share touched a 52 week high of $5.9 on and a 52 week low of $0.6 on . I-mab stock price today i.e. is closed at $3.69,which is 37.46% down from its 52 week high and 520.17% up from its 52 week low.

What is I-mab's market capitalisation today?

I-mab market capitalisation is $0.00T as on .

How to invest in I-mab Stock (IMAB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for I-mab on INDmoney app. Click on Buy button. You can invest as low as $1.5 in I-mab Shares that will get you 0.4065 shares as per I-mab share price of $3.69 per share as on September 18, 2025 at 1:29 am IST.

What is the minimum amount required to buy I-mab Stock (IMAB) from India?

Indian investors can start investing in I-mab (IMAB) shares with as little as ₹87.816 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹878.16 in I-mab stock (as per the Rupee-Dollar exchange rate as on ). Based on I-mab share’s latest price of $3.69 as on September 18, 2025 at 1:29 am IST, you will get 2.7100 shares of I-mab. Learn more about fractional shares .